MAGNANI, ELIANA

MAGNANI, ELIANA  

Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino (NEUROFARBA)  

Mostra records
Risultati 1 - 12 di 12 (tempo di esecuzione: 0.026 secondi).
Titolo Data di pubblicazione Autore(i) File
Accuracy of the central vein sign evaluation by brain MRI for the pathologic characterization of multiple sclerosis cases with markers of "better explanation" of the diagnosis. 2017 M, Grammatico; Carlucci, G; Dalla Giacoma, S; Vuolo, L; Repice, Am; Mechi, C; Magnani, E; Barilaro, A; Fainardi, E; Massacesi, L.
Association of celiac disease in patients with multiple sclerosis in Tuscany 2020 Piccini, Barbara; Ulivelli, Monica; Amato, Maria Pia; Bartalini, Sabina; Falcini, Mario; Giannini, Marta; Magnani, Eliana; Massacesi, Luca; Repice, Anna Maria; Vascotto, Marina; Grosso, Salvatore
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 2019 Mechi, C; Mariottini, A; Pasca, M; Forci, B; Magnani, E; Barilaro, A; Repice, AM; Massacesi, L
Differentiation by MRI between multiple sclerosis and MS-like syndromes with markers of "better explanation" of the diagnosis. 2017 M., Grammatico; Dallagiacoma, S.; Lorenzoni, L.; Carlucci, G.; Repice, A. M.; Mechi, C.; Magnani, E.; Vuolo, L.; Fainardi, E.; Massacesi, L.
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 2019 Forci, B; Mariottini, A; Mechi, C; Magnani, E; Barilaro, A; Falcini, M; Palumbo, P; Massacesi, L; Repice, AM
Leptomeningeal enhancement analysis in diagnostic clinical setting 2015 Vuolo, L; Repice, AM; Mechi, C; Magnani, E; Forci, B; Massacesi, L
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. 2015 Clausi, V; Giannecchini, S; Magnani, E; Repice, A; Mechi, C; Martelli, F; Azzi, A; Massacesi, L.
MRI evaluation of the "central vein sign" in brain white matter lesions of multiple sclerosis and systemic autoimmune diseases. 2016 Vuolo, L.; Emmi, G.; Carlucci, G.; Repice, A.; Magnani, E.; Spagni, G.; Prisco, D.; Silvestri, E.; Barilaro, A.; Sati, P.; Reich, D.; Massacesi, L.
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 2017 Forci, B; Mariottini, A; Mechi, C; Magnani, E; Barilaro, A; Massacesi, L; Repice, A
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis. 2019 Mariottini A, Innocenti C, Forci B, Magnani E, Mechi C, Barilaro A, Nistri R, Fani A, Saccardi R, Massacesi L, Repice AM.
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 2017 Mariottini, A; Forci, B; Magnani, E; Massacesi, L; Repice, A
The diagnosis of multiple sclerosis with markers of "better explanation": accuracy of the "central vein sign" in uncovering pathogenic mechansms different from inflammatory demyelination 2018 Grammatico, M; Carlucci, G; Dallagiacoma, S; Vuolo, L; Repice, AM; Mechi, C; Magnani, E; Barilaro, A; Massacesi, L